@genomicscow.bsky.social
Original and probably disagreeable perspectives on genomics. Not sure when I'm joking and when I'm being serious. Opinions my own, not the herd’s.
Pinned
#Genomics on social media is mainstream. Kinda boring.
Don't follow the herd
Don't follow the herd
What took Xenium so long to get protein panels out? These were touted several years ago
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
August 20, 2025 at 3:48 PM
What took Xenium so long to get protein panels out? These were touted several years ago
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
- Resources taken from Xenium?
- Resources in Xenium but needed for other features or bugs to fix?
- Chemistry was poorly optimized for dev teams to finalized?
But one answer can’t be true: lack of demand.
Just saw that Somalogic nabbed a big win 👏
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study | Standard BioTools Inc.
The Investor Relations website contains information about Standard BioTools Inc.'s business for stockholders, potential investors, and financial analysts.
investors.standardbio.com
August 13, 2025 at 11:57 AM
Just saw that Somalogic nabbed a big win 👏
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
1. Big non European cohort doing proteomics 👍
2. Competition where SomaScan won 🥇
3. But now Illumina buying Somalogic to run on NGS🦈
4. But why generate this data on a microarray platform w limited future? 🤷♀️
investors.standardbio.com/news-release...
Company posting message about how important their products are
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
July 14, 2025 at 7:49 PM
Company posting message about how important their products are
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
…and backing this up with a picture of their Chief-anything-Officer with a quote about how much we should believe this
#imsold!
🐮
Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎
www.nytimes.com/2025/06/30/w...
www.nytimes.com/2025/06/30/w...
What Makes Someone Cool? A New Study Offers Clues.
www.nytimes.com
July 11, 2025 at 5:48 PM
Now waiting for some GWAS studies followed to find cool genes, followed by analyses on how coolness is confounded by mating behavior 😎
www.nytimes.com/2025/06/30/w...
www.nytimes.com/2025/06/30/w...
So we will see illumina at HUPO this year?
June 23, 2025 at 5:00 PM
So we will see illumina at HUPO this year?
Such timing.
Not the LinkedIn part though, that’s still boring
Not the LinkedIn part though, that’s still boring
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
June 6, 2025 at 6:19 PM
Such timing.
Not the LinkedIn part though, that’s still boring
Not the LinkedIn part though, that’s still boring
Call me heartless if you want, but I’m a bit jaded with this pitch:
“Someone I knew had a disease, so I started a company…”
“Someone I knew had a disease, so I started a company…”
June 6, 2025 at 9:53 AM
Call me heartless if you want, but I’m a bit jaded with this pitch:
“Someone I knew had a disease, so I started a company…”
“Someone I knew had a disease, so I started a company…”
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
June 4, 2025 at 5:08 PM
Imagine if people were honest on LinkedIn:
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
Instead of congratulating someone on their new role,
“This person burned their bridges”
Till then, LinkedIn is just one big self-advertising platform
🐮
May 24, 2025 at 12:58 PM
May 23, 2025 at 4:18 PM
Reposted
You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you
The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission
The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission
May 16, 2025 at 6:00 PM
You can’t eat microchips. Social media can’t heal the sick. B2B SaaS will never love you
The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission
The final measure of any technology is the value it creates, directly or indirectly, for living things. In this sense, biology is everyone’s mission
Excited and bearish on proteomics risk scores. I hear how they compare favorably to polygenic risk scores
But, polygenic risk scores already perform far better than incumbents
Performance isn’t the issue
To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure
But, polygenic risk scores already perform far better than incumbents
Performance isn’t the issue
To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure
May 16, 2025 at 4:19 PM
Excited and bearish on proteomics risk scores. I hear how they compare favorably to polygenic risk scores
But, polygenic risk scores already perform far better than incumbents
Performance isn’t the issue
To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure
But, polygenic risk scores already perform far better than incumbents
Performance isn’t the issue
To be clear, proteins have many advantages (dynamic, possible with existing dx infrastructure
A relief, followed with regret on wasting energy on emergency meetings for many, I’ll bet
Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables
Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables
US, China Temporarily Slash Tariffs After Life Sciences Firms Prepared for Impact
US, China Temporarily Slash Tariffs After Life Sciences Firms Prepared for Impact
www.genomeweb.com
May 14, 2025 at 2:41 PM
A relief, followed with regret on wasting energy on emergency meetings for many, I’ll bet
Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables
Meanwhile illumina isn’t likely to do well in China for a while yet, not just for instruments but probably also consumables
Last I read of Vinay Prasad he was generally against large genomics panels for cancer testing - though with reasonable rebuttals
Wow his career really took a turn (and off!) from those days!
Wow his career really took a turn (and off!) from those days!
May 11, 2025 at 7:53 PM
Last I read of Vinay Prasad he was generally against large genomics panels for cancer testing - though with reasonable rebuttals
Wow his career really took a turn (and off!) from those days!
Wow his career really took a turn (and off!) from those days!
Fearless, maybe also safe prediction: 2025 is the rise of the fractional CXOs in genomics
May 9, 2025 at 9:36 PM
Fearless, maybe also safe prediction: 2025 is the rise of the fractional CXOs in genomics
Companies have been letting go a lot of staff recently
But the firing of Kári Stefánsson from decode in Iceland really sticks out
Sounds like Amgen couldn’t be too endless with the popgen programs
But the firing of Kári Stefánsson from decode in Iceland really sticks out
Sounds like Amgen couldn’t be too endless with the popgen programs
May 7, 2025 at 6:31 PM
Companies have been letting go a lot of staff recently
But the firing of Kári Stefánsson from decode in Iceland really sticks out
Sounds like Amgen couldn’t be too endless with the popgen programs
But the firing of Kári Stefánsson from decode in Iceland really sticks out
Sounds like Amgen couldn’t be too endless with the popgen programs
“Are you still interested in genomics?”
Illumina just sent this to me, giving uninterested ppl a chance to unsubscribe
Appreciate the politeness but it’s timing reinforces meekness
Illumina just sent this to me, giving uninterested ppl a chance to unsubscribe
Appreciate the politeness but it’s timing reinforces meekness
April 30, 2025 at 3:26 PM
“Are you still interested in genomics?”
Illumina just sent this to me, giving uninterested ppl a chance to unsubscribe
Appreciate the politeness but it’s timing reinforces meekness
Illumina just sent this to me, giving uninterested ppl a chance to unsubscribe
Appreciate the politeness but it’s timing reinforces meekness
Assemble a polygenic risk score for a trait and get an AUC of 0.75
Add some dynamic ‘ome like RNA, methylation or protein and get that number to 0.8+
This hypothetical is a significant improvement but who’s gonna afford 2+ omics to validate your combinatorial signature?
Add some dynamic ‘ome like RNA, methylation or protein and get that number to 0.8+
This hypothetical is a significant improvement but who’s gonna afford 2+ omics to validate your combinatorial signature?
April 22, 2025 at 9:17 PM
Assemble a polygenic risk score for a trait and get an AUC of 0.75
Add some dynamic ‘ome like RNA, methylation or protein and get that number to 0.8+
This hypothetical is a significant improvement but who’s gonna afford 2+ omics to validate your combinatorial signature?
Add some dynamic ‘ome like RNA, methylation or protein and get that number to 0.8+
This hypothetical is a significant improvement but who’s gonna afford 2+ omics to validate your combinatorial signature?
Who is using Chat programs to get through publications quicker?
Any tricks that you can share that makes this process effective?
Any tricks that you can share that makes this process effective?
April 13, 2025 at 8:33 PM
Who is using Chat programs to get through publications quicker?
Any tricks that you can share that makes this process effective?
Any tricks that you can share that makes this process effective?
Feelings sympathy for the Chinese illumina team writing quotes this past last week
There is a glut of alternatives but those who forget, projects shouldn’t just switch sequencers midway
There is a glut of alternatives but those who forget, projects shouldn’t just switch sequencers midway
April 12, 2025 at 10:03 AM
Feelings sympathy for the Chinese illumina team writing quotes this past last week
There is a glut of alternatives but those who forget, projects shouldn’t just switch sequencers midway
There is a glut of alternatives but those who forget, projects shouldn’t just switch sequencers midway
Illumina is dead, long live illumina!
April 3, 2025 at 10:30 AM
Illumina is dead, long live illumina!
The next 23andMe might be using proteins (calling themselves 20andMe) and try healthcare DTC and still fail
It’s hard to see individual-driven healthcare becoming a hung beyond the executive programs
It’s hard to see individual-driven healthcare becoming a hung beyond the executive programs
March 29, 2025 at 2:59 PM
The next 23andMe might be using proteins (calling themselves 20andMe) and try healthcare DTC and still fail
It’s hard to see individual-driven healthcare becoming a hung beyond the executive programs
It’s hard to see individual-driven healthcare becoming a hung beyond the executive programs
Unfortunately if you didn’t guess it already, sounds like Q1 results and updates to 2025 forecasts are gonna be a disappointment for life science firms all over. Instability in funds means taking on less risky investments. Company forecasts don’t get met with “safe wins”
March 23, 2025 at 2:12 PM
Unfortunately if you didn’t guess it already, sounds like Q1 results and updates to 2025 forecasts are gonna be a disappointment for life science firms all over. Instability in funds means taking on less risky investments. Company forecasts don’t get met with “safe wins”
Alright can someone just run a soma olink study using dozens if not more spikes in proteins along a dilution curve?
March 10, 2025 at 4:44 PM
Alright can someone just run a soma olink study using dozens if not more spikes in proteins along a dilution curve?
A nice collection of agbt articles written by genomeweb. Even the headlines alone will help you down memory lane of technologies and respect the history of this conference
www.genomeweb.com/sequencing/a...
www.genomeweb.com/sequencing/a...
AGBT Turns 25: A Short History of Genome Technology
The meeting has hosted a succession of technology launches, marking the shift from Sanger to next-generation sequencing and, more recently, to spatial and multiomics platforms.
www.genomeweb.com
March 7, 2025 at 11:01 PM
A nice collection of agbt articles written by genomeweb. Even the headlines alone will help you down memory lane of technologies and respect the history of this conference
www.genomeweb.com/sequencing/a...
www.genomeweb.com/sequencing/a...